Literature DB >> 19269046

The apparent cooperativity of some GPCRs does not necessarily imply dimerization.

Marc Chabre1, Philippe Deterre, Bruno Antonny.   

Abstract

When the binding of one ligand to its receptor is influenced by a second ligand acting on a different receptor, one might assume that the receptors dimerize, enabling allosteric interactions between ligands. This reasoning is frequently used to explain the complex binding curves of ligands of class A G-protein-coupled receptors (GPCRs). Here, we argue that in classical in vitro experiments the lack of GTP makes ligand-binding properties dependent on the available pool of G protein. Under such conditions a 1:1 GPCR-G-protein complex is stabilized, in which the G protein lacks a nucleotide and ligand binding is of high affinity. In vivo, this complex, a key intermediate of G-protein activation, never accumulates because of fast and irreversible GTP binding. In vitro, this complex creates interference in ligand binding when two monomeric GPCRs compete for the same G protein. Interestingly, this competition explains some in vivo effects of orphan GPCRs.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19269046     DOI: 10.1016/j.tips.2009.01.003

Source DB:  PubMed          Journal:  Trends Pharmacol Sci        ISSN: 0165-6147            Impact factor:   14.819


  41 in total

Review 1.  Allostery at G protein-coupled receptor homo- and heteromers: uncharted pharmacological landscapes.

Authors:  Nicola J Smith; Graeme Milligan
Journal:  Pharmacol Rev       Date:  2010-12       Impact factor: 25.468

2.  G-protein-coupled receptor heteromer dynamics.

Authors:  Jean-Pierre Vilardaga; Luigi F Agnati; Kjell Fuxe; Francisco Ciruela
Journal:  J Cell Sci       Date:  2010-12-15       Impact factor: 5.285

3.  Gi/o-coupled receptors compete for signaling to adenylyl cyclase in SH-SY5Y cells and reduce opioid-mediated cAMP overshoot.

Authors:  Erica S Levitt; Lauren C Purington; John R Traynor
Journal:  Mol Pharmacol       Date:  2010-11-22       Impact factor: 4.436

4.  HIV-1 exploits CCR5 conformational heterogeneity to escape inhibition by chemokines.

Authors:  Philippe Colin; Yann Bénureau; Isabelle Staropoli; Yongjin Wang; Nuria Gonzalez; Jose Alcami; Oliver Hartley; Anne Brelot; Fernando Arenzana-Seisdedos; Bernard Lagane
Journal:  Proc Natl Acad Sci U S A       Date:  2013-05-21       Impact factor: 11.205

5.  Evidence for activity-regulated hormone-binding cooperativity across glycoprotein hormone receptor homomers.

Authors:  Maxime Zoenen; Eneko Urizar; Stéphane Swillens; Gilbert Vassart; Sabine Costagliola
Journal:  Nat Commun       Date:  2012       Impact factor: 14.919

6.  Targeting spare CC chemokine receptor 5 (CCR5) as a principle to inhibit HIV-1 entry.

Authors:  Jun Jin; Philippe Colin; Isabelle Staropoli; Evelyne Lima-Fernandes; Cécile Ferret; Arzu Demir; Sophie Rogée; Oliver Hartley; Clotilde Randriamampita; Mark G H Scott; Stefano Marullo; Nathalie Sauvonnet; Fernando Arenzana-Seisdedos; Bernard Lagane; Anne Brelot
Journal:  J Biol Chem       Date:  2014-05-22       Impact factor: 5.157

7.  Hetero-oligomerization of CCR2, CCR5, and CXCR4 and the protean effects of "selective" antagonists.

Authors:  Denis Sohy; Hideaki Yano; Patricia de Nadai; Eneko Urizar; Aude Guillabert; Jonathan A Javitch; Marc Parmentier; Jean-Yves Springael
Journal:  J Biol Chem       Date:  2009-09-15       Impact factor: 5.157

8.  The oligomeric state sets GABA(B) receptor signalling efficacy.

Authors:  Laëtitia Comps-Agrar; Julie Kniazeff; Lenea Nørskov-Lauritsen; Damien Maurel; Martin Gassmann; Nathalie Gregor; Laurent Prézeau; Bernhard Bettler; Thierry Durroux; Eric Trinquet; Jean-Philippe Pin
Journal:  EMBO J       Date:  2011-05-06       Impact factor: 11.598

9.  Multiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.

Authors:  Reem Berro; Per Johan Klasse; Danny Lascano; Ayanna Flegler; Kirsten A Nagashima; Rogier W Sanders; Thomas P Sakmar; Thomas J Hope; John P Moore
Journal:  J Virol       Date:  2011-06-15       Impact factor: 5.103

Review 10.  International Union of Basic and Clinical Pharmacology. XCV. Recent advances in the understanding of the pharmacology and biological roles of relaxin family peptide receptors 1-4, the receptors for relaxin family peptides.

Authors:  Michelle L Halls; Ross A D Bathgate; Steve W Sutton; Thomas B Dschietzig; Roger J Summers
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.